Background
Anti-Müllerian hormone (AMH) is an atypical hormone, as its circulating levels are predominantly determined by size of the endocrine gland (i.e. number and type of ovarian follicles). Thus, ovarian reserve is the dominant influence on circulating levels of AMH, accounting for 55~75% of the variance in this hormone in premenopausal women (Fanchin et al., 2003; Hansen et al., 2011; Bentzen et al., 2013) . The lesser determinants of AMH levels are incompletely known, and are the subject of current controversy, arising from differences in methodology. When studies involve repeated measurement from the same individual, then circulating AMH levels appear to be influenced by the ovarian cycle (Hadlow et al., 2013) , pregnancy (Nelson et al., 2010; Koninger et al., 2013; Hamilton et al., 2016; Pankhurst et al., 2016b) and vitamin D status (Dennis et al., 2012) . In contrast, when the study group involves either a single AMH value per women or averaged AMH values from multiple women, variable conclusions have been reached, with negative findings being commonly reported for pregnancy (La Marca et al., 2005; Lutterodt et al., 2009 ) and vitamin D status, both previously (Chang et al., 2014; Pearce et al., 2015; Neville et al., 2016) and now (Drakopoulos et al., 2016) in this issue. In some instances, the negative results generated are false, leading to controversy within the literature. This commentary discusses the circumstances when methodological issues arise in AMH research and gives examples of robust, efficient alternative methodologies.
Controlling for ovarian reserve
The levels of most hormones are dynamically regulated, with the size of the endocrine gland having little or no influence. Under this circumstance, the absolute levels of hormones strongly correlate with their dynamic determinants. AMH, however, is the polar opposite of this generalization, as organ size (ovarian reserve) is the dominant influence on serum AMH levels. This complicates the detection of dynamic regulation of AMH (AMH production per follicle), as its influence on population variance in serum AMH is small compared to that of ovarian reserve.
When studies involve repeated measures (e.g. stage of the ovarian cycle, before/after treatment), the data can be normalized to the log of a woman's initial AMH value, thus removing ovarian reserve from the analysis. In this circumstance, variation in AMH per follicle would be expected to lead to a similar variation of AMH in the circulation. The group size needed to test hypotheses with high statistical certainty in this circumstance is relatively small, particularly when the response to the regulation is relatively invariant between women. AMH putatively acts locally within the ovary, through mechanisms such as modulation of the response of follicles to FSH . The functions of circulating AMH are uncertain, and possibly unrelated to primary determinants of fertility (McLennan and Pankhurst, 2015) . Two women can have identical levels of AMH in their follicles, but have >100-fold difference in their serum AMH levels, as circulating AMH levels are the product of follicle number and the mean AMH per follicle. Variation in serum AMH is therefore only weakly linked to variation in AMH levels per follicle. When serum AMH is correlated to putative regulators of AMH production, then the expected effect size is small. This is because up to 80% of the difference in serum AMH levels between women is due to ovarian reserve and the ovarian cycle, leaving only 20% for all other influences. The regulation of AMH production per follicle is likely to be complex (Malloy et al., 2009; Merhi et al., 2013) . Therefore, a regulator may have substantial effects on AMH production at the level of the follicle but may only contribute only 1-2% of the total variation in circulating AMH levels. Very large group sizes are needed to detect influences that account for 1-2% of overall variation.
The absence of evidence is not evidence of absence. The studies that have reported negative associations between serum AMH and putative regulators (e.g. the ovarian cycle, vitamin D) have been insufficiently powered to detect biologically relevant changes that are occurring at the level of the follicle. Such studies are evidence that regulators of AMH production have minimal influence on the population distribution of serum AMH levels, but such studies lack the power to reach conclusions about whether a putative regulator influences AMH levels in an individual. That is, studies using normalized and raw AMH values are both valid, but are testing different hypotheses. Normalized data enables the ovarian function of individual women to be tested. Raw serum AMH levels test whether a regulator contributes to population variation in serum AMH (unless the group size is massive); problems emerge with this type of study, when negative results are presented as disproof of hypotheses relating to clinically relevant ovarian biology.
Use of averaged raw data
When variation over time is examined, then the proportional change in each individual should be examined. When averaged raw AMH values are used, then the calculated magnitude of any variation does not report the mean variation occurring in the participants. A simple illustration of this is presented in the supplementary table. This issue also applies to the sole estimation of the plasma half-life of AMH in women (Griesinger et al., 2012) . When the initial values of all participants in a time series are broadly similar, then the method of calculation has limited effect on the estimated mean value. For example, the inter-person variation of estrogen levels on day 0 of the ovarian cycle is small relative to the difference between the Day 0 and the pre-ovulatory levels of each woman. The issue of whether estrogen levels are averaged or not is consequently a matter of little importance. AMH is the converse, as variation in the initial value between women on Day 0 is large relative to the change occurring during the cycle. Averaging here creates cryptic weighting of data (Supplementary Table S1 ) and other issues, with this issue being sufficiently severe to distort conclusions. The issues associated with averaging can be bypassed by various methods, depending of the objectives of the study. For example, the data can be normalized to each woman's initial value (Hadlow et al., 2013; Pankhurst et al., 2016a,b) or repeated measures statistical analyses can be used. In some instances, generating the ratio of serum AMH and small antral follicle counts will provide novel insight.
One additional advantage of examining individual women is that instability in AMH levels can be detected. For example, there is no difference on average between AMH levels before conception and the first trimester (Hamilton et al., 2016) . Similarly there is no difference, on average, between post-partum AMH and first trimester AMH levels (Pankhurst et al., 2016a,b) . However, AMH levels fluctuate during these periods, with AMH levels increasing in some women, and decreasing in others, with few women exhibiting unchanged levels of AMH. Despite the clear evidence of variability, there is no difference on average as the increases and decreases cancel each other out (Hamilton et al., 2016; Pankhurst et al., 2016a,b) .
Recruitment demographics
The composition of the developing follicle pool and biological variability in AMH differs substantially between young women and women of advanced reproductive age (Bentzen et al., 2013; Robertson et al., 2014; Hadlow et al., 2016) . When women of diverse age are included in a single cohort, then statistical variation is increased, and the data is an aggregation of women of differing biology. Moving forward, we argue that the analyses of the regulation of the ovary should typically involve cohorts of women of similar ovarian characteristics or cohorts that are stratified based on the woman's ovarian reserve (Sowers et al., 2010) .
Confounding influence of historic regulation
The regulation of hormone levels is typically transient: insulin levels are acutely regulated by plasma glucose levels, but a transient rise in insulin on one day does not alter insulin levels decades later. AMH also appears to be an exception to this principle, as AMH is both the product of ovarian follicles, and a probable determinant of the rate at which follicles are used. Hence, if a factor directly up-regulates AMH synthesis, then a young woman with a deficiency in the factor will typically produce less AMH per ovarian follicle. In isolation of other influences (see next section), this may accelerate the depletion of her ovarian reserve, leading to lower levels of AMH in later life. Theoretically, the effect of historic regulation of AMH should be cumulative over time. As women age, their circulating AMH levels may thus progressively reflect historic regulation, with a diminishing influence of current regulation. If so, there is no a priori reason to predict that circulating levels of AMH should reflect the levels of a putative regulator on a single day, particularly when the study group includes older women who have undergone numerous ovarian cycles. This is potentially leading to confusion in the literature. For example, the observation that AMH levels change in parallel to seasonal fluctuation in vitamin D levels (Dennis et al., 2012) are not necessarily inconsistent with observations that AMH and vitamin D levels do not strongly associate on a particular day (Chang et al., 2014; Pearce et al., 2015; Neville et al., 2016) . The former study examined current dynamic regulation with limited or no historic influence (Dennis et al., 2012) , whereas the later approach examined both current and historic regulation (Chang et al., 2014; Pearce et al., 2015; Drakopoulos et al., 2016; Neville et al., 2016) , with lesser statistical power (due to recruitment demographics).
Historic regulation of AMH may be multifaceted
Most regulators of cellular behaviours are pleiotropic, with context dependent actions that can have both positive and negative influences on complex traits, such as ovarian reserve or fertility. Simple assumptions can rarely be made when analysing the influence of a deficiency or excess of a regulator over decades. For example, vitamin D can increase AMH synthesis through activation of the AMH genepromoter (Malloy et al., 2009) . In isolation, this would suggest that vitamin D deficiency would lead to increased rate of follicle usage, thus accelerating the decline in ovarian reserve. However, vitamin D influences the down-regulation of the AMH receptor in granulosa cells under some circumstances (Merhi et al., 2014) . Vitamin D is also a regulator of multiple other cell types, including pituitary neurons (Bhattarai et al., 2016) and adipose cells (Abbas, 2016) , which influence follicle use through humeral influences (Merhi et al., 2013) . Consequently, the effect of vitamin D on follicle use is the sum of multiple mechanisms, some of which will be positive and some negative. Therefore it is currently unclear whether vitamin D status has a positive, neutral or negative influence on ovarian reserve. A crosssectional analysis of vitamin D levels and ovarian reserve (or its proxy, AMH) does not resolve this question, as vitamin D levels are not constant across time. The understanding of the influence of vitamin D levels on bones is underpinned by the analysis of individuals (human and animals) whose vitamin D status is constant (or known) over time (Christakos et al., 2016) . In our view, these studies provide a template for how the role of a putative regulator of AMH or ovarian reserve should be tested.
Analytical considerations
The latest generation of commercial AMH assays have improved sensitivity, with little or no matrix interference (Li et al., 2016; Pigny et al., 2016) . The correlation between the assays is high (R > 0.9) across the range of AMH values, although the relationship between concentrations is not 1:1 (Li et al., 2016; Pigny et al., 2016) . The ranking of AMH values is therefore more highly conserved than the absolute values. This is partly because an international standard has yet to be established to enable comparison between platforms. Additionally, circulating AMH is a mixture of proAMH and AMH N,C with current assays providing an aggregate measure of the two AMH species (Pankhurst et al., 2014) , which differ in their receptor binding characteristics (di Clemente et al., 2010) . The relative levels of proAMH and AMH N,C vary between individuals (Pankhurst et al., 2016a,b) , creating platformspecific variation whenever the two species are not equivalently detected. This appears to be a minor issue when estimating ovarian reserve. However, knowledge of the relative levels of proAMH and AMH N,C is essential to understand how AMH influences biological processes such as the responsiveness of follicles to FSH. Commercial AMH-form specific assays are not available, but the Beckman Coulter Gen II assay can be readily converted to specifically measure proAMH for research purposes (Pankhurst and McLennan, 2016) .
Conclusion
Absolute levels of AMH are an excellent biomarker for ovarian reserve, as ovarian reserve accounts for a high proportion of the biological variation in AMH levels. However, the flip side of this is that biological and clinically important regulation of AMH production within follicles will be difficult to detect in the circulation, unless efficient methodology is used. In many instances, this can be achieved by using data that is normalized to an individual, preferably using groups of women with similar ovarian reserve, thus enabling life-cycle related changes in ovarian biology to be detected.
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